Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

3.2K
Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
3.2K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

7.0K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.0K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

5.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.9K
Distinctive Features of Adult Stem Cells vs Cancer Stem Cells01:18

Distinctive Features of Adult Stem Cells vs Cancer Stem Cells

4.5K
A stem cell is an unspecialized cell that can divide without limit as needed and can, under specific conditions, differentiate into specialized cells.
Adult stem cells
Adult stem cells are tissue-specific; hence, they divide to develop the tissue from which they originate. One type of adult stem cell is the epithelial stem cell, which gives rise to the keratinocytes in the multiple layers of epithelial cells in the epidermis of the skin. Adult bone marrow has three distinct types of stem cells:...
4.5K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

14.7K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.7K
Cancer02:18

Cancer

53.9K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
53.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cell Cycle Sensing Shapes Human T Cell Fate and Exhaustion Programs.

bioRxiv : the preprint server for biology·2026
Same author

Cell-autonomous control of CAR signaling and receptor shedding via ADAM17-mediated proteolysis.

Cell·2026
Same author

Dynamics of BCMA expression in patients with relapsed/refractory multiple myeloma receiving BCMA-directed CAR-T therapy.

Blood cancer journal·2026
Same author

Predictive biomarkers of response to chimeric antigen receptor (CAR) T-cell therapy for pan-haematologic cancer.

Nature biomedical engineering·2026
Same author

Engineering chimeric antigen receptor CD4 T cells for Alzheimer's disease.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

c-JUN enhances CRISPR knockin anti-B7-H3 CAR T cell function in small cell lung cancer and thoracic SMARCA4-deficient undifferentiated tumors.

Cell reports. Medicine·2026
Same journal

Lab-on-a-disc biosensing platform for folate level quantification.

Nature biomedical engineering·2026
Same journal

BoneCoT: multicentre validation of a whole-body skeleton foundation model for bone metastases guided by clinician-derived chain of thought.

Nature biomedical engineering·2026
Same journal

Derivation of functional retinal endothelial cells from human pluripotent stem cells for therapeutics and modelling.

Nature biomedical engineering·2026
Same journal

Engineered circular RNA compatible with complete nucleoside modification and rolling circle translation through a Cap-independent translation enhancer.

Nature biomedical engineering·2026
Same journal

The evolving role of cytokines for CAR-T cell manufacturing and beyond.

Nature biomedical engineering·2026
Same journal

Off‑the‑shelf, engineered non-living stem cell strategy for advancing cellular therapies.

Nature biomedical engineering·2026
See all related articles

Related Experiment Video

Updated: Jan 26, 2026

A Spheroid Killing Assay by CAR T Cells
08:19

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

17.2K

Programming CAR-T cells to kill cancer.

Louai Labanieh1, Robbie G Majzner2, Crystal L Mackall3,4,5

  • 1Department of Bioengineering, Stanford University, Stanford, CA, USA.

Nature Biomedical Engineering
|April 24, 2019
PubMed
Summary
This summary is machine-generated.

Next-generation chimeric antigen receptor (CAR)-T cell therapies show promise for treating blood cancers and solid tumors. Engineering strategies enhance CAR-T cell potency, specificity, and persistence, addressing current treatment challenges.

More Related Videos

Production of Human CRISPR-Engineered CAR-T Cells
06:33

Production of Human CRISPR-Engineered CAR-T Cells

Published on: March 15, 2021

14.4K
Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo
05:14

Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo

Published on: July 25, 2025

814

Related Experiment Videos

Last Updated: Jan 26, 2026

A Spheroid Killing Assay by CAR T Cells
08:19

A Spheroid Killing Assay by CAR T Cells

Published on: December 12, 2018

17.2K
Production of Human CRISPR-Engineered CAR-T Cells
06:33

Production of Human CRISPR-Engineered CAR-T Cells

Published on: March 15, 2021

14.4K
Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo
05:14

Studying Interactions between Myeloid Cells and CAR T Cells In Vitro and In Vivo

Published on: July 25, 2025

814

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology
  • Cellular Therapy

Background:

  • Chimeric antigen receptor (CAR)-T cell therapy has shown significant success in hematologic malignancies.
  • Challenges remain, including treatment toxicities, tumor relapse, and targeting solid tumors due to antigen scarcity and immunosuppressive microenvironments.
  • Genetic engineering of T cells offers potential solutions to enhance CAR-T cell therapy.

Purpose of the Study:

  • To review advances in engineering next-generation CAR-T cell therapies for both hematologic and solid cancers.
  • To highlight strategies for controlling CAR specificity and activity.
  • To discuss approaches for improving CAR-T cell persistence and overcoming immunosuppression.

Main Methods:

  • Review of current literature on CAR-T cell engineering and therapeutic applications.
  • Focus on genetic modification strategies for enhanced CAR-T cell function.
  • Analysis of methods to improve CAR-T cell persistence and overcome tumor microenvironment-mediated immunosuppression.

Main Results:

  • Significant progress has been made in engineering CAR-T cells with improved specificity and potency.
  • Strategies to enhance T cell persistence and overcome immunosuppression are crucial for therapeutic efficacy.
  • Next-generation CAR-T cell designs are being developed to address limitations of current therapies.

Conclusions:

  • Advanced genetic engineering of CAR-T cells is key to overcoming challenges in treating both hematologic and solid tumors.
  • Future directions include developing 'off-the-shelf' CAR-T cell products for broader accessibility.
  • Continued innovation in CAR-T cell therapy holds promise for more effective cancer treatment.